• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Payman Khales to assume the role of Integer Chief Operating Officer and Andrew Senn to become President, Cardio & Vascular in the first quarter of 2025

    10/24/24 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $ITGR alert in real time by email

    PLANO, Texas, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading medical device contract development and manufacturing organization (CDMO), today announced that Payman Khales will assume the newly created role of Chief Operating Officer during the first quarter of 2025. Andrew Senn will take Mr. Khales' place as the President, Cardio & Vascular at the same time.

    Mr. Khales joined the Company in early 2018 and has served as the President, Cardio & Vascular. Under his leadership, this business has accelerated its sales and market penetration and achieved above-market growth.

    As Integer's Chief Operating Officer, Mr. Khales will oversee both of Integer's product categories (Cardio & Vascular and Cardiac Rhythm Management & Neuromodulation) along with Global Operations and Manufacturing Strategy. "The role of COO will be focused on sharing best practices between the product categories and enhancing the execution and speed of Integer's global operational excellence initiatives," said Joe Dziedzic, Integer's President and Chief Executive Officer.

    Mr. Senn has been with Integer for eighteen years, including fifteen years in our Cardio & Vascular product category, and his most recent executive role has been Senior Vice President, Strategy, Business Development, and Investor Relations. Mr. Senn will apply his deep technical knowledge and extensive leadership experience gained through program management, research and development, marketing, and sales roles at Integer and St. Jude Medical, to further guide the Cardio & Vascular product category along its growth journey.

    "During his time with Integer, Payman has done an exceptional job leading the global Cardio & Vascular product category by establishing a successful market/customer-based strategy that has driven above market growth and improved profitability. With his proven expertise in commercial business leadership and his deep understanding of Integer's product development and manufacturing operations, he is uniquely positioned to take on a greater responsibility within the Company," said Mr. Dziedzic. He added, "Andrew has served successfully in many roles at Integer, from research and development to sales to the head of corporate strategy. He has a deep knowledge of the industry and a strong customer focus and is ideally suited to continue the growth of our Cardio & Vascular business."

    Mr. Khales said, "I am honored to become Integer's Chief Operating Officer and look forward to working closely with Jim Stephens (President CRM&N), John Harris (EVP, Global Operations and Manufacturing Strategy) and Andrew in his new role. Together we will continue to serve our customers through development of high-quality complex products and processes, achieving above-market growth over the long term."

    Before joining Integer, Mr. Khales served as President of the Environmental Technologies business segment for CECO Environmental Corp., a diversified global provider of engineered technologies to the environmental, energy, and fluid handling and filtration industrial segments. Prior to that, he held several progressive executive leadership roles at Ingersoll Rand Company.

    Mr. Khales holds an Executive Master of Business Administration from Indiana University's Kelley School of Business, and a Bachelor of Science in Mechanical Engineering from École Polytechnique de Montréal.

    Mr. Senn was Director of Program Management responsible for electrophysiology systems at St. Jude Medical prior to joining Integer.

    Mr. Senn holds a Master of Business Administration with concentrations in Finance, Marketing and Medical Industry Leadership from the Carlson School of Management at the University of Minnesota and a Master of Science in Technology Management, Bachelor of Science in Mechanical Engineering and a Bachelor of Arts in Business Administration from the University of St. Thomas.

    About Integer®

    Integer Holdings Corporation (NYSE:ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets. As a strategic partner of choice to medical device companies and OEMs, Integer is committed to enhancing the lives of patients worldwide by providing innovative, high-quality products and solutions. The company's brands include Greatbatch Medical® and Lake Region Medical®. Additional information is available at www.integer.net.

    Investor Relations:              

    Andrew Senn                         

    [email protected]      

    763.951.8312                         
    Media Relations:

    Kelly Butler

    [email protected] 

    469.731.6617


    Primary Logo

    Get the next $ITGR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Q&A

    New
    • Who will be the new Chief Operating Officer of Integer Holdings Corporation?

      Integer Holdings Corporation has appointed Payman Khales as the new Chief Operating Officer starting in the first quarter of 2025.

    • Who will replace Payman Khales as President, Cardio & Vascular?

      Andrew Senn will take over as the President of the Cardio & Vascular division.

    • What achievements has Payman Khales accomplished during his tenure at Integer Holdings Corporation?

      Payman Khales has been integral in driving sales and market penetration within the Cardio & Vascular product category, resulting in above-market growth under his leadership.

    • What will be Payman Khales' responsibilities as Chief Operating Officer?

      As COO, Khales will focus on overseeing the Cardio & Vascular and Cardiac Rhythm Management & Neuromodulation categories, as well as enhancing global operational excellence initiatives.

    • What roles did Payman Khales hold before joining Integer Holdings Corporation?

      Prior to joining Integer, Khales held executive roles at CECO Environmental Corp. and Ingersoll Rand Company, showcasing extensive leadership experience.

    Recent Analyst Ratings for
    $ITGR

    DatePrice TargetRatingAnalyst
    2/20/2026$95.00Hold → Buy
    The Benchmark Company
    10/24/2025Buy → Hold
    Argus
    10/24/2025$80.00Overweight → Equal Weight
    Wells Fargo
    10/24/2025$77.00Buy → Neutral
    Citigroup
    10/24/2025$87.00Buy → Neutral
    BofA Securities
    10/24/2025Buy → Hold
    The Benchmark Company
    5/22/2025$140.00Neutral → Buy
    Citigroup
    3/28/2025$145.00Outperform
    Raymond James
    More analyst ratings

    $ITGR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Harris John A

    4 - Integer Holdings Corp (0001114483) (Issuer)

    4/2/26 4:28:54 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Kapito Aaron

    4 - Integer Holdings Corp (0001114483) (Issuer)

    3/25/26 9:38:52 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Carr Terence

    4 - Integer Holdings Corp (0001114483) (Issuer)

    3/25/26 9:38:47 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ITGR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Integer Announces Board Leadership Transition

    PLANO, Texas, April 06, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today announced Pamela G. Bailey, who currently serves as Integer's independent Chair of the Board, will not stand for re-election at the Company's 2026 Annual Meeting of Stockholders, scheduled for May 20, 2026. Following the Annual Meeting, the Board intends to appoint current director Donald J. Spence to serve as independent Chair of the Board. "It has been a privilege to serve on the Integer Board and to play my part in the Company's growth and strategic success," said Ms. Bailey. "I am confident that und

    4/6/26 5:00:51 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer Appoints James Flanagan and Aaron Kapito to Board of Directors

    ~ Enters into Cooperation Agreement with Irenic Capital Management ~  PLANO, Texas, March 12, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today announced that James Flanagan has been appointed to the Board of Directors (the "Board") as an independent director. Additionally, in connection with a cooperation agreement with Irenic Capital Management, LP (together with its affiliates, "Irenic"), Aaron Kapito has also been appointed to the Board. "The Board looks forward to welcoming James and Aaron as new independent directors and benefiting from their complementary perspectives

    3/12/26 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer to Participate at Upcoming Investor Conferences

    PLANO, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading medical device contract development and manufacturing organization, today announced that members of its executive leadership team will participate in the following investor conferences in March: Raymond James 47th Annual Institutional Investors Conference, 11:35 a.m. ET, March 3Oppenheimer 36th Annual Healthcare MedTech & Services Conference, 12:40 p.m. ET, March 17KeyBanc Capital Markets Healthcare Forum, 11:15 a.m. ET, March 18 A live webcast and replay for each event will be accessible under "News & Events" on the Investor Relations section of Integer's website at investor.integer.net.

    2/24/26 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ITGR
    SEC Filings

    View All

    SEC Form DEFA14A filed by Integer Holdings Corporation

    DEFA14A - Integer Holdings Corp (0001114483) (Filer)

    4/6/26 4:57:04 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form DEF 14A filed by Integer Holdings Corporation

    DEF 14A - Integer Holdings Corp (0001114483) (Filer)

    4/6/26 4:56:04 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Integer Holdings Corporation

    SCHEDULE 13G/A - Integer Holdings Corp (0001114483) (Subject)

    3/27/26 9:55:06 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ITGR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Global Ops and Manufactur Harris John A bought $115,500 worth of shares (1,650 units at $70.00), increasing direct ownership by 37% to 6,066 units (SEC Form 4)

    4 - Integer Holdings Corp (0001114483) (Issuer)

    11/13/25 4:18:50 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EVP, Chief Financial Officer Smith Diron bought $74,967 worth of shares (1,116 units at $67.19), increasing direct ownership by 17% to 7,698 units (SEC Form 4)

    4 - Integer Holdings Corp (0001114483) (Issuer)

    11/10/25 8:19:02 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Capps Cheryl C bought $106,720 worth of shares (1,600 units at $66.70), increasing direct ownership by 16% to 11,702 units (SEC Form 4)

    4 - Integer Holdings Corp (0001114483) (Issuer)

    11/10/25 8:16:21 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ITGR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Integer Holdings upgraded by The Benchmark Company with a new price target

    The Benchmark Company upgraded Integer Holdings from Hold to Buy and set a new price target of $95.00

    2/20/26 8:20:06 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer Holdings downgraded by Argus

    Argus downgraded Integer Holdings from Buy to Hold

    10/24/25 2:15:30 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer Holdings downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Integer Holdings from Overweight to Equal Weight and set a new price target of $80.00

    10/24/25 8:57:52 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ITGR
    Leadership Updates

    Live Leadership Updates

    View All

    Integer Announces Board Leadership Transition

    PLANO, Texas, April 06, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today announced Pamela G. Bailey, who currently serves as Integer's independent Chair of the Board, will not stand for re-election at the Company's 2026 Annual Meeting of Stockholders, scheduled for May 20, 2026. Following the Annual Meeting, the Board intends to appoint current director Donald J. Spence to serve as independent Chair of the Board. "It has been a privilege to serve on the Integer Board and to play my part in the Company's growth and strategic success," said Ms. Bailey. "I am confident that und

    4/6/26 5:00:51 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer Appoints James Flanagan and Aaron Kapito to Board of Directors

    ~ Enters into Cooperation Agreement with Irenic Capital Management ~  PLANO, Texas, March 12, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today announced that James Flanagan has been appointed to the Board of Directors (the "Board") as an independent director. Additionally, in connection with a cooperation agreement with Irenic Capital Management, LP (together with its affiliates, "Irenic"), Aaron Kapito has also been appointed to the Board. "The Board looks forward to welcoming James and Aaron as new independent directors and benefiting from their complementary perspectives

    3/12/26 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Payman Khales Assumes Role as Integer President and CEO

    ~ Planned Leadership Transition Completed ~ PLANO, Texas, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today shared that, as part of a planned transition originally announced in April 2025, Payman Khales has assumed the role of President and Chief Executive Officer. He also joins the company's Board of Directors. He succeeds Joseph Dziedzic, who is retiring after eight years of distinguished service as Integer President and CEO and will continue to serve as an advisor through March 31, 2026, to support a smooth transition. Mr. Khales joined Integer in 2018 as Preside

    10/24/25 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ITGR
    Financials

    Live finance-specific insights

    View All

    Integer Holdings Corporation Reports Results for Fourth Quarter and Full Year 2025

    ~ Delivered 8% sales growth and 21% adjusted EPS growth in full year 2025 ~ ~ 2026 Outlook maintains midpoint of sales growth and high end of adjusted EPS growth from October outlook ~~ Continue to expect 200bps above-market organic sales growth in 2027 ~ PLANO, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading contract development and manufacturing organization, today announced results for the three and twelve months ended December 31, 2025. Unless otherwise stated, all results and comparisons are from continuing operations. Fourth Quarter 2025 Financial Results (compared to fourth quarter 2024, except as noted) Sales increased 5% to $472 mill

    2/19/26 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer Announces Conference Call to Discuss Fourth Quarter and Full Year 2025 Results

    PLANO, Texas, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) announced today that it will webcast its conference call discussing financial results and business highlights for the fourth quarter and year ended Dec. 31, 2025, on Thursday, Feb. 19, 2026, at 8 a.m. CT / 9 a.m. ET. Other forward-looking and material information may also be discussed during this call. The company will issue a news release announcing financial results for the fourth quarter and full year on Feb. 19 prior to the conference call. Conference call details: Date: Thursday, Feb. 19, 2026Time: 8 a.m. CT / 9 a.m. ETDomestic dial-in number: (800) 715-9871International dial-in number: (646) 30

    1/22/26 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer Holdings Corporation Reports Third Quarter 2025 Results

    ~ Continued strong sales and profit growth in 3Q25 ~~ Updating 2025 sales and profit outlook; providing preliminary outlooks for 2026 and 2027 ~ PLANO, Texas, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) today announced results for the three months ended September 26, 2025. Third Quarter 2025 Highlights (compared to Third Quarter 2024, except as noted) Sales increased 8% to $468 million, with organic growth of 7%.GAAP operating income decreased $2 million to $56 million, a decrease of 3%. Non-GAAP adjusted operating income increased $10 million to $86 million, an increase of 14%.GAAP income from continuing operations increased $3 million to $40 million, an

    10/23/25 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ITGR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Integer Holdings Corporation (Amendment)

    SC 13G/A - Integer Holdings Corp (0001114483) (Subject)

    2/9/24 9:59:01 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Integer Holdings Corporation (Amendment)

    SC 13G/A - Integer Holdings Corp (0001114483) (Subject)

    1/30/24 1:15:44 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Integer Holdings Corporation (Amendment)

    SC 13G/A - Integer Holdings Corp (0001114483) (Subject)

    2/10/23 2:42:23 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care